Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.

Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.

Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.

Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.

Abstract: Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.

Abstract: Devices that include multi-reservoir infusion devices and systems for dispensing compositions for the treatment of subjects with an amylin agonist (e.g., the amylin agonist analog, pramlintide), wherein amylin agonists are administered in certain differential bolus and basal ratios to an administered insulin, as well as methods, compositions, and kits and articles of manufacture comprising said compositions for use in the treatment of responsive patients with an amylin and an insulin in ratios thereof that are distinct for bolus and basal administration.

Abstract: Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.

Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.

Abstract: Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.

Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.

Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.

Abstract: Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.

Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.

Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.

Abstract: Provided herein are methods of treating obesity and diabetes with labile bile acid sequestrants. An effective amount of a labile bile acid sequestrant may be orally administered to an obese or diabetic individual. A labile bile acid sequestrant provided herein may have a low affinity in the colon or rectum of a human for at least one bile acid or bile acid mimic that stimulates L-cells. A labile bile acid sequestrant may be a non-systemic labile bile acid sequestrant.

Abstract: A packaging apparatus for enclosing a head portion of a stethoscope in a barrier material. The packaging apparatus includes a housing having an interior with an opening for allowing the insertion of a head portion of a stethoscope into the interior. A sensor assembly detects the insertion of the head portion of the stethoscope. A door assembly selectively closes the opening. The door assembly comprises a door member and a door actuator. The door member is movable between an open position and a closed position. A vacuum assembly evacuates air from the interior. A table member supports a section of a roll of barrier material comprising individual plastic sleeves. A feed assembly positions the barrier material. A handling assembly manipulates an open end of the sleeves. The handling assembly includes an upper attachment member and a lower attachment member for releasably attaching to top and bottom sides of the open end of the sleeve respectively.

Abstract: "Two-site" or "sandwich" immunometric assay techniques for determination of the presence and/or concentration of antigenic substances in fluids using monoclonal antibodies are described and compared to conventional assays using polyclonal antibodies. Also described are inhibition assays using complexes of antigens with a monoclonal antibody.

Abstract: "Two-site" or "sandwich" immunometric assay techniques for determination of the presence and/or concentration of antigenic substances in fluids using monoclonal antibodies. One monoclonal antibody is presented in a soluble labeled form and a second monoclonal antibody is presented bound to a solid carrier; the soluble and bound monoclonal antibodies may be the products of either the same or different cell lines. Each monoclonal antibody has an affinity for the antigenic substances of at least about 10.sup.8 liters/mole.

Abstract: Polyimide prepolymers formed by thermo-reactions of an aliphatic bismaleimide, where the aliphatic group is a polyaliphatic ether, with an aromatic bismaleimide and/or an aromatic diamine in combination with a trismaleimide which are curable upon addition of an acid catalyst and/or heating to about 65.degree. C.

Abstract: Polyimide prepolymers formed by thermo-reactions of an aliphatic bismaleimide, where the aliphatic group is a polyaliphatic ether, with an aromatic bismaleimide and/or an aromatic diamine in combination with a cross-linking agent having at least two vinyl groups provide compositions which are curable at low temperatures, i.e., 65.degree. C. or less.